SCOPUS 정보 검색 플랫폼

Chromatographia

Volumn 73, Issue 3-4, 2011, Pages 257-262

HPLC-MS-MS for the simultaneous determination of atorvastatin and amlodipine in plasma of hypertensive patients

(7) Yu, Qi a Hu, Zhe Yi b Zhu, Fan Yuan c Zhu, Jin Hui a Wan, Li Li a Li, Yan a Guo, Cheng a

a SHANGHAI JIAO TONG UNIVERSITY (China)

b SHANGHAI INSTITUTE OF MATERIA MEDICA (China)

c SECOND MILITARY MEDICAL UNIVERSITY (China)

Author keywords

Amlodipine; Atorvastatin; High performance liquid chromatography; Plasma samples; Tandem mass spectrometry

Indexed keywords

AMLODIPINE; ATORVASTATIN; NITRENDIPINE;

ACCURACY; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG MONITORING; DRUG STABILITY; DRUG STRUCTURE; DYSLIPIDEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYPERTENSION; PLASMA; PRIORITY JOURNAL; STANDARD; TANDEM MASS SPECTROMETRY;

EID: 79951774863 PISSN: 00095893 EISSN: 16121112 Source Type: Journal
DOI: 10.1007/s10337-010-1883-4 Document Type: Article

Times cited : (23)

References (19)

1
- 69349103701
- doi:10.1016/j.ijcard.2009.07.002
- Koh KK, Quon MJ, Han SH, Lee Y, Park JB, Kim SJ, Koh Y, Shin EK (2009) Int J Cardiol. doi: 10.1016/j.ijcard.2009.07.002
- (2009) Int J Cardiol.
- Koh, K.K.¹ Quon, M.J.² Han, S.H.³ Lee, Y.⁴ Park, J.B.⁵ Kim, S.J.⁶ Koh, Y.⁷ Shin, E.K.⁸

2
- 1242296772
- Amlodipine and atorvastatin in atherosclerosis: A review of the potential of combination therapy
- DOI 10.1517/14656566.5.2.459
- JW Jukema JW van der Hoorn 2004 Expert Opin Pharmacother 5 459 468 10.1517/14656566.5.2.459 1:CAS:528:DC%2BD2cXmvVKntA%3D%3D 10.1517/14656566.5.2. 459 (Pubitemid 38219871)
- (2004) Expert Opinion on Pharmacotherapy , vol.5 , Issue.2 , pp. 459-468
- Jukema, J.W.¹ Van Der Hoorn, J.W.A.²

3
- 37849033559
- 10.1002/jssc.200700148 1:CAS:528:DC%2BD1cXmt1GrsQ%3D%3D 10.1002/jssc.200700148
- T Sivakumar R Manavalan C Muralidharan K Valliappan 2007 J Sep Sci 30 3143 3153 10.1002/jssc.200700148 1:CAS:528:DC%2BD1cXmt1GrsQ%3D%3D 10.1002/jssc.200700148
- (2007) J Sep Sci , vol.30 , pp. 3143-3153
- Sivakumar, T.¹ Manavalan, R.² Muralidharan, C.³ Valliappan, K.⁴

4
- 0025860978
- 10.1021/jm00110a012 1:CAS:528:DyaK3MXktVSitrk%3D 10.1021/jm00110a012
- FP Guengerich WR Brian M Iwasaki MA Sari C Bäärnhielm P Berntsson 1991 J Med Chem 34 1838 1844 10.1021/jm00110a012 1:CAS:528: DyaK3MXktVSitrk%3D 10.1021/jm00110a012
- (1991) J Med Chem , vol.34 , pp. 1838-1844
- Guengerich, F.P.¹ Brian, W.R.² Iwasaki, M.³ Sari, M.A.⁴ Bäärnhielm, C.⁵ Berntsson, P.⁶

5
- 39749109979
- 10.2165/0129784-200808010-00007 1:CAS:528:DC%2BD1cXltFCqsro%3D 10.2165/00129784-200808010-00007
- K McKeage MA Siddiqui 2008 Am J Cardiovasc Drugs 8 51 67 10.2165/0129784-200808010-00007 1:CAS:528:DC%2BD1cXltFCqsro%3D 10.2165/00129784-200808010-00007
- (2008) Am J Cardiovasc Drugs , vol.8 , pp. 51-67
- McKeage, K.¹ Siddiqui, M.A.²

6
- 0033783036
- 1:CAS:528:DC%2BD3cXnsFOlsbs%3D
- W Jacobsen B Kuhn A Soldner G Kirchner KF Sewing PA Kollman LZ Benet U Christians 2000 Drug Metab Dispos 28 1369 1378 1:CAS:528:DC%2BD3cXnsFOlsbs%3D
- (2000) Drug Metab Dispos , vol.28 , pp. 1369-1378
- Jacobsen, W.¹ Kuhn, B.² Soldner, A.³ Kirchner, G.⁴ Sewing, K.F.⁵ Kollman, P.A.⁶ Benet, L.Z.⁷ Christians, U.⁸

7
- 45549089673
- Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors
- DOI 10.2165/00002018-200831070-00004
- E Molden E Skovlund P Braathen 2008 Drug Saf 31 587 596 10.2165/00002018-200831070-00004 1:CAS:528:DC%2BD1cXpslKms78%3D 10.2165/00002018-200831070-00004 (Pubitemid 351861951)
- (2008) Drug Safety , vol.31 , Issue.7 , pp. 587-596
- Molden, E.¹ Skovlund, E.² Braathen, P.³

8
- 33645007118
- SA Wilson A Sanford 2006 Am Fam Physician 73 1067 1068
- (2006) Am Fam Physician , vol.73 , pp. 1067-1068
- Wilson, S.A.¹ Sanford, A.²

9
- 69249127425
- 1:CAS:528:DC%2BD1MXht1anurnN
- Q Zou Y Zhan Z Ge P Wei P Ouyang 2009 Arzneimittelforschung 59 383 391 1:CAS:528:DC%2BD1MXht1anurnN
- (2009) Arzneimittelforschung , vol.59 , pp. 383-391
- Zou, Q.¹ Zhan, Y.² Ge, Z.³ Wei, P.⁴ Ouyang, P.⁵

10
- 67651214387
- 10.1002/bmc.1161 1:CAS:528:DC%2BD1MXmt1CmtL4%3D 10.1002/bmc.1161
- AV Ramani P Sengupta R Mullangi 2009 Biomed Chromatogr 23 615 622 10.1002/bmc.1161 1:CAS:528:DC%2BD1MXmt1CmtL4%3D 10.1002/bmc.1161
- (2009) Biomed Chromatogr , vol.23 , pp. 615-622
- Ramani, A.V.¹ Sengupta, P.² Mullangi, R.³

11
- 33847017209
- 10.1002/bmc.730 1:CAS:528:DC%2BD2sXitVKkurs%3D 10.1002/bmc.730
- J Bhatt S Singh G Subbaiah B Shah S Kambli S Ameta 2007 Biomed Chromatogr 21 169 175 10.1002/bmc.730 1:CAS:528:DC%2BD2sXitVKkurs%3D 10.1002/bmc.730
- (2007) Biomed Chromatogr , vol.21 , pp. 169-175
- Bhatt, J.¹ Singh, S.² Subbaiah, G.³ Shah, B.⁴ Kambli, S.⁵ Ameta, S.⁶

12
- 67649173103
- 10.1016/j.jchromb.2009.05.052 10.1016/j.jchromb.2009.05.052
- L Nováková H Vlcková D Satínský P Sadílek D Solichová M Bláha V Bláha P Solich 2009 J Chromatogr B Analyt Technol Biomed Life Sci 877 2093 2103 10.1016/j.jchromb. 2009.05.052 10.1016/j.jchromb.2009.05.052
- (2009) J Chromatogr B Analyt Technol Biomed Life Sci , vol.877 , pp. 2093-2103
- Nováková, L.¹ Vlcková, H.² Satínský, D.³ Sadílek, P.⁴ Solichová, D.⁵ Bláha, M.⁶ Bláha, V.⁷ Solich, P.⁸

13
- 34250011211
- Chromatography-mass spectrometry methods for the quantitation of statins in biological samples
- DOI 10.1016/j.jpba.2007.02.008, PII S0731708507001203, Hyphenated Techniques in Pharmaceutical and Biomedical Analysis 2006
- R Nirogi K Mudigonda V Kandikere 2007 J Pharm Biomed Anal 44 379 387 10.1016/j.jpba.2007.02.008 1:CAS:528:DC%2BD2sXmtlagurg%3D 10.1016/j.jpba.2007. 02.008 (Pubitemid 46887638)
- (2007) Journal of Pharmaceutical and Biomedical Analysis , vol.44 , Issue.2 , pp. 379-387
- Nirogi, R.¹ Mudigonda, K.² Kandikere, V.³

14
- 79951771607
- doi:10.1002/bmc.1462
- Pilli NR, Inamadugu JK, Mullangi R, Karra VK, Vaidya JR, Seshagiri Rao JV (2010) Biomed Chromatogr. doi: 10.1002/bmc.1462
- (2010) Biomed Chromatogr
- Pilli, N.R.¹ Inamadugu, J.K.² Mullangi, R.³ Karra, V.K.⁴ Vaidya, J.R.⁵ Seshagiri Rao, J.V.⁶

15
- 33747036402
- Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet
- DOI 10.1177/0091270006291031
- M Chung A Calcagni P Glue C Bramson 2006 J Clin Pharmacol 46 1030 1037 10.1177/0091270006291031 1:CAS:528:DC%2BD28XpvFOmsLk%3D 10.1177/0091270006291031 (Pubitemid 44215068)
- (2006) Journal of Clinical Pharmacology , vol.46 , Issue.9 , pp. 1030-1037
- Chung, M.¹ Calcagni, A.² Glue, P.³ Bramson, C.⁴

16
- 0003484310
- U.S. FDA Guidance for Industry on Bioanalytical Method Validation (2001) ( http://www.fda.gov/cder/guidance/index.htm )
- (2001) U.S. FDA Guidance for Industry on Bioanalytical Method Validation

17
- 0037663202
- Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS
- DOI 10.1021/ac020361s
- BK Matuszewski ML Constanzer CM Chavez-Eng 2003 Anal Chem 75 3019 3030 10.1021/ac020361s 1:CAS:528:DC%2BD3sXltV2jsL8%3D 10.1021/ac020361s (Pubitemid 36830428)
- (2003) Analytical Chemistry , vol.75 , Issue.13 , pp. 3019-3030
- Matuszewski, B.K.¹ Constanzer, M.L.² Chavez-Eng, C.M.³

18
- 77955251731
- 10.1016/j.clinthera.2010.07.004 1:CAS:528:DC%2BC3cXht1yjtrbO 10.1016/j.clinthera.2010.07.004
- YM Liu HH Pu GY Liu JY Jia LP Weng RJ Xu GX Li W Wang MQ Zhang C Lu C Yu 2010 Clin Ther 32 1396 1407 10.1016/j.clinthera.2010.07.004 1:CAS:528: DC%2BC3cXht1yjtrbO 10.1016/j.clinthera.2010.07.004
- (2010) Clin Ther , vol.32 , pp. 1396-1407
- Liu, Y.M.¹ Pu, H.H.² Liu, G.Y.³ Jia, J.Y.⁴ Weng, L.P.⁵ Xu, R.J.⁶ Li, G.X.⁷ Wang, W.⁸ Zhang, M.Q.⁹ Lu, C.¹⁰ Yu, C.¹¹

19
- 65549153100
- 10.1016/j.clinthera.2009.04.013 1:CAS:528:DC%2BD1MXmsFelsLg%3D 10.1016/j.clinthera.2009.04.013
- Y Liu J Jia G Liu S Li C Lu Y Liu C Yu 2009 Clin Ther 31 777 783 10.1016/j.clinthera.2009.04.013 1:CAS:528:DC%2BD1MXmsFelsLg%3D 10.1016/j.clinthera.2009.04.013
- (2009) Clin Ther , vol.31 , pp. 777-783
- Liu, Y.¹ Jia, J.² Liu, G.³ Li, S.⁴ Lu, C.⁵ Liu, Y.⁶ Yu, C.⁷

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.